A victim of its own progress: why the success of modern therapeutics forces a re-evaluation of placebo-controlled trials in migraine prevention.

Lev N, Borovoi L, Elefant E, Domany E, Daniel O, Ifergane G

Open source

DOI
10.3389/fneur.2026.1871028
Published
2026
Container
Frontiers in neurology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fneur.2026.1871028,
  title = {A victim of its own progress: why the success of modern therapeutics forces a re-evaluation of placebo-controlled trials in migraine prevention.},
  author = {Lev N and Borovoi L and Elefant E and Domany E and Daniel O and Ifergane G},
  year = {2026},
  journal = {Frontiers in neurology},
  doi = {10.3389/fneur.2026.1871028},
  url = {https://doi.org/10.3389/fneur.2026.1871028}
}

RIS

TY  - JOUR
TI  - A victim of its own progress: why the success of modern therapeutics forces a re-evaluation of placebo-controlled trials in migraine prevention.
AU  - Lev N
AU  - Borovoi L
AU  - Elefant E
AU  - Domany E
AU  - Daniel O
AU  - Ifergane G
PY  - 2026
JO  - Frontiers in neurology
DO  - 10.3389/fneur.2026.1871028
UR  - https://doi.org/10.3389/fneur.2026.1871028
ER  - 

APA

N, L., L, B., E, E., E, D., O, D., & G, I. (2026). A victim of its own progress: why the success of modern therapeutics forces a re-evaluation of placebo-controlled trials in migraine prevention.. Frontiers in neurology. https://doi.org/10.3389/fneur.2026.1871028

Source records